The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
LLM 2021 | Limitations of CAR T-cell therapy for DLBCL
Adrienne Phillips, MD, Weill Cornell Medicine, New York, NY, shares her thoughts on immunotherapies for relapsed diffuse large B-cell lymphoma (DLBCL). Whilst autologous chimeric antigen receptor (CAR) T-cells have been approved to treat DLBCL, they take a long time to be manufactured, they cannot be manufactured everywhere, and not all patients respond well to CAR T-cell therapy. It is therefore important to develop other effective therapies. Dr Phillips explains that bi-specific T-cell engagers (BiTEs) represent a promising alternative to CAR T-cell therapy. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
